WO2008139056A1 - Procede de preparation du 2-(n-butyl)-5-nitrobenzofurane - Google Patents
Procede de preparation du 2-(n-butyl)-5-nitrobenzofurane Download PDFInfo
- Publication number
- WO2008139056A1 WO2008139056A1 PCT/FR2008/000471 FR2008000471W WO2008139056A1 WO 2008139056 A1 WO2008139056 A1 WO 2008139056A1 FR 2008000471 W FR2008000471 W FR 2008000471W WO 2008139056 A1 WO2008139056 A1 WO 2008139056A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- butyl
- nitrobenzofuran
- nitrophenol
- hex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
Definitions
- the present invention relates to a process for the preparation of 2- (n-butyl) -5-nitrobenzofuran of formula:
- Dronedarone and its salts has been described in the European patent application EP 471609. This product is particularly interesting as an anti-arrhythmic agent and has applications in the cardiovascular field and in particular for the prevention of certain types of mortality after myocardial infarction.
- the preparation of the dronedarone is carried out via 2- (n-butyl) -5-nitrobenzofuran.
- the preparation of 2- (n-butyl) -5-nitrobenzofuran is carried out from 2-hydroxy-5-nitrobromobenzyl and involves a reaction using triphenylphosphine to prepare 2-hydroxy-5-nitrobenzyltriphenylphosphonium bromide.
- triphenylphosphine it was necessary to find an efficient industrial process avoiding the use of 2-hydroxy-5-nitrobromobenzyl, expensive precursor and to access this intermediate molecule whose preparation generated a large amount of waste, in particular the oxide of triphenylphosphine.
- WO-A 01/28974 and WO-A 01/29019 disclose a process for preparing 5-nitrobenzofuran from salicylic aldehyde and comprising 4 steps via intermediates such as 2- (2-formyl) -4-acid. -nitrophenoxy) carboxylic acid.
- intermediates such as 2- (2-formyl) -4-acid. -nitrophenoxy) carboxylic acid.
- the use of salicylic acid is expensive and the presence of aldehyde functions on the intermediates makes the process sensitive to oxidation.
- the halogen of 1-halogeno-4-nitrobenzene is advantageously chosen from fluorine or chlorine.
- Step a) consists of the preparation of 4-nitrophenyl-1-vinylbutyl ether.
- the reaction step a) of 1-hexen-3-ol on 1-halogeno-4-nitrobenzene is carried out according to known methods which do not affect the rest of the molecule, especially after deprotonation of the alcohol in the presence of a mineral or organic base, in a homogeneous or heterogeneous medium, preferably in the presence of an alkaline hydride (for example sodium hydride), or of an alkaline carbonate (for example the sodium or potassium carbonate).
- an alkaline hydride for example sodium hydride
- an alkaline carbonate for example the sodium or potassium carbonate
- step b) Claisen rearrangement of 4-nitrophenyl-1 vinylbutyl ether in 2- (hex-2-en-1-yl) -4-nitrophenol is carried out by thermal activation or in the presence of catalysts, in particular it is carried out by heating at temperatures above 100 ° C., with or without a solvent .
- the rearrangement is carried out in the presence of a protic polar solvent (in particular in a hydro-alcoholic medium, for example in an ethanol-water medium), or in the presence of a slightly polar aprotic or apolar aprotic solvent, especially in ethers (for example: di-isopropyl ether or diphenyl ether), in hydrocarbons or halogenated solvents (for example o-dichlorobenzene or trichlorobenzene) or in the presence of a mixture of the abovementioned solvents, at a temperature of between 100 and 260 ° C., and more particularly between 150 and 180 ° C.
- 2- (hex-2-en-1-yl) -4-nitrophenol of formula (III) is a novel product which is also within the scope of the present invention.
- step c) of catalytic intramolecular cyclization of 2- (hex-2-en-1-yl) -4-nitrophenol to 2- (n-butyl) -5-nitrobenzofuran is carried out from nitrophenol derivative of formula (III) by a catalytic process, in the presence of platinum group metals, preferentially palladium and more particularly palladium salts ", in the presence or absence of an organic or inorganic base and an agent. organic or mineral oxidant (especially in the presence of dissolved oxygen).
- the reaction is carried out in the presence of a Pd - salt (such as, for example, the halides or the carboxylates, in particular the palladium chloride and palladium acetate) (for example with phosphines or nitriles, preferentially bis (benzonitrile) chloride.
- a Pd - salt such as, for example, the halides or the carboxylates, in particular the palladium chloride and palladium acetate
- phosphines or nitriles preferentially bis (benzonitrile) chloride.
- palladium (II) [PdCl 2 (PhCN) 2 ] or bis (acetonitrile) palladium (II) chloride [PdCl 2 (MeCN) 2 ]) or non-liganded.
- the base is advantageously chosen from alkaline salts such as alkali metal carbonates or bicarbonates or carboxylates (sodium or potassium carbonate, sodium or potassium bicarbonate for example, sodium acetate for example) or organic bases such as nitrogenous bases (triethylamine for example), and one acts in the presence of an organic oxidizing agent (such as benzoquinone), mineral such as copper salts (copper acetate for example) or in the presence of a gaseous oxidizing agent (dissolved oxygen), in an aprotic or apolar aprotic weak polar organic solvent such as an ether (dioxane, tetrahydrofuran for example) or in an aromatic hydrocarbon (xylene for example) or in an aprotic polar solvent (such as acetonitrile for example) ) or in a mixture of the aforementioned solvents, at a temperature between 20 ° C and the reflux temperature of the reaction mixture.
- an organic oxidizing agent such as benzoquinone
- the catalytic amounts are between 0.1 and 1 equivalent.
- the reaction is carried out in the presence of bis (benzonitrile) palladium (II) chloride in the presence of an organic oxidizing agent such as benzoquinone, and sodium carbonate.
- the products obtained according to steps a) to c) can be purified by chromatography.
- the present invention is particularly interesting because of its Claisen rearrangement and intramolecular cyclization steps, which are particularly selective and lead to high yields.
- the cyclization of 2- (hex-2-en-1-yl) -4-nitrophenol rapidly and selectively leads to 2- (n-butyl) -5-nitrobenzofuran without chromene formation, under mild catalytic conditions.
- the dronedarone can be obtained from 2- (n-butyl) -5-nitrobenzofuran, for example according to the method described in the European patent application EP 471609.
- a solution of 1-fluoro-4-nitrobenzene (28.4 mmol) in dimethylformamide (12 ml) at a flow rate of 0.5 ml / min is added at 26 ° C.
- the addition is accompanied by a slight exotherm (+ 4 ° C).
- the mixture is maintained for 3 hours 30 minutes at 26 ° C. with stirring.
- the crude reaction mixture is slowly poured into a saturated aqueous solution of ammonium chloride with stirring; the exotherm is controlled by an ice-water bath (5 ° C) so that the temperature of the mixture does not exceed 30 ° C. Stirring is maintained for another 15 minutes.
- Example C cyclization with benzofuran (1 equivalent of catalyst)
- a 50 ml three-necked flask equipped with a magnetic bar, placed on a magnetic stirrer, are successively introduced 100 mg (0.452 mmol) of 2- (hex-2-en-1-yl) -4-nitrophenol, 173 mg.
- 48 mg (0.452 mmol) of sodium carbonate 49 mg of 1,4-benzoquinone and 30 ml of 1, A-dioxane.
- Example D cyclization with benzofuran (0.1 equivalent of catalyst) In an 8 ml pillbox equipped with a magnetic bar, placed on a magnetic heating stirrer, 8.7 mg (0.023 mmol) of bis ( benzonitrile) -palladium (II) [PdCl 2 (PhCN) 2 ], 24 mg (0.225 mmol) of sodium carbonate, 25 mg (0.225 mmol) of 1,4-benzoquinone and 4 ml of 1,4-dioxane.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Furan Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200880014112A CN101687764A (zh) | 2007-04-06 | 2008-04-04 | 2-正丁基-5-硝基苯并呋喃的制备方法 |
| CA002683304A CA2683304A1 (fr) | 2007-04-06 | 2008-04-04 | Procede de preparation du 2-(n-butyl)-5-nitrobenzofurane |
| US12/594,861 US20110009649A1 (en) | 2007-04-06 | 2008-04-04 | METHOD FOR PREPARING 2-(n-BUTYL)-5-NITROBENZOFURAN |
| EP08787910A EP2144866A1 (fr) | 2007-04-06 | 2008-04-04 | Procede de preparation du 2-(n-butyl)-5-nitrobenzofurane |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0702543A FR2914643B1 (fr) | 2007-04-06 | 2007-04-06 | Procede de preparation du 2-(n-butyl)-5-nitrobenzofurane |
| FR0702543 | 2007-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008139056A1 true WO2008139056A1 (fr) | 2008-11-20 |
Family
ID=38669913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/FR2008/000471 Ceased WO2008139056A1 (fr) | 2007-04-06 | 2008-04-04 | Procede de preparation du 2-(n-butyl)-5-nitrobenzofurane |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110009649A1 (fr) |
| EP (1) | EP2144866A1 (fr) |
| CN (1) | CN101687764A (fr) |
| CA (1) | CA2683304A1 (fr) |
| FR (1) | FR2914643B1 (fr) |
| WO (1) | WO2008139056A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006017594A1 (de) * | 2006-04-13 | 2007-10-18 | Wacker Chemie Ag | Neuartige Ru-Komplexe, deren Herstellung und Verwendung |
| WO2012032545A1 (fr) | 2010-09-08 | 2012-03-15 | Cadila Healthcare Limited | Procédé pour préparer un dérivé de benzofurane et des produits intermédiaires de celui-ci |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996005190A1 (fr) * | 1994-08-11 | 1996-02-22 | Karo Bio Ab | Derives de 3-benzoyle benzofurane en tant qu'antagonistes de l'hormone thyroidienne |
| WO2001029019A1 (fr) * | 1999-10-21 | 2001-04-26 | Rhodia Chimie | Procede de preparation d'un compose de type benzofurane ou benzothiophene |
| EP1394155A2 (fr) * | 2002-08-19 | 2004-03-03 | Bayer Chemicals AG | 5-Nitrobenzofuranes |
-
2007
- 2007-04-06 FR FR0702543A patent/FR2914643B1/fr not_active Expired - Fee Related
-
2008
- 2008-04-04 CN CN200880014112A patent/CN101687764A/zh active Pending
- 2008-04-04 US US12/594,861 patent/US20110009649A1/en not_active Abandoned
- 2008-04-04 CA CA002683304A patent/CA2683304A1/fr not_active Abandoned
- 2008-04-04 WO PCT/FR2008/000471 patent/WO2008139056A1/fr not_active Ceased
- 2008-04-04 EP EP08787910A patent/EP2144866A1/fr not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996005190A1 (fr) * | 1994-08-11 | 1996-02-22 | Karo Bio Ab | Derives de 3-benzoyle benzofurane en tant qu'antagonistes de l'hormone thyroidienne |
| WO2001029019A1 (fr) * | 1999-10-21 | 2001-04-26 | Rhodia Chimie | Procede de preparation d'un compose de type benzofurane ou benzothiophene |
| EP1394155A2 (fr) * | 2002-08-19 | 2004-03-03 | Bayer Chemicals AG | 5-Nitrobenzofuranes |
Non-Patent Citations (1)
| Title |
|---|
| KITAMURA, TSUGIO ET AL: "Aromatic C-H insertion of .beta.-phenoxyalkylidenecarbenes generated by reaction of alkynyl(p-phenylene)bisiodonium ditrifluoromethanesulfonates (ditriflates) with phenoxide anions", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 2: PHYSICAL ORGANIC CHEMISTRY , (8), 1511-1515 CODEN: JCPKBH; ISSN: 0300-9580, 1997, XP002459252 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2914643B1 (fr) | 2009-06-05 |
| CN101687764A (zh) | 2010-03-31 |
| CA2683304A1 (fr) | 2008-11-20 |
| EP2144866A1 (fr) | 2010-01-20 |
| US20110009649A1 (en) | 2011-01-13 |
| FR2914643A1 (fr) | 2008-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2429422C (fr) | Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese | |
| EP1351907B1 (fr) | Chlorhydrate du 2-butyl-3-(4-'3-(dibutylamino)propoxy]benzoyl)-5-nitro-benzofurane et sa preparation | |
| CN115772155B (zh) | 一种α-硫辛酸中间体的制备方法 | |
| CA2773064C (fr) | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable | |
| EP2144866A1 (fr) | Procede de preparation du 2-(n-butyl)-5-nitrobenzofurane | |
| WO2008152217A2 (fr) | Procede de preparation du 2-(n-butyu-5-nitrobenzofurane | |
| WO2008139057A2 (fr) | Procede de preparation de 2-(n-butyl)-3-(4-hydroxybenzoyl)-5-nitrobenzofurane | |
| EP2730562B1 (fr) | Nouveau procédé de synthèse du (2E)-3-(3,4-dimethoxyphényl)prop-2-enenitrile, et application à la synthèse de l'ivabradine et de ses sels d'addition à un acide pharmaceutiquement acceptable | |
| KR20230117260A (ko) | 1-(3,5-디클로로페닐)-2,2,2-트리플루오로에타논 및그의 유도체의 제조 방법 | |
| WO2008090078A1 (fr) | Procede de synthese de la rhein et de ses derives | |
| CA2835459C (fr) | Nouveau procede de synthese du 3-(2-bromo-4,5-dimethoxyphenyl)propanenitrile, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable | |
| CA2829428C (fr) | Nouveau procede de synthese du 3-(2-bromo-4,5-dimethoxyphenyl)propanenitrile, et application a la synthese de l`ivabradine et de ses sels d`addition a un acide pharmaceutiquement acceptable | |
| FR2460951A1 (fr) | Procede de preparation de derives de 15-hydroxyimino-e-homoeburnane et composes obtenus par ce procede | |
| EP0611232A1 (fr) | Procédé pour la préparatiuon de dérivés phénylbenzamides | |
| FR2766821A1 (fr) | Derives de 1,3-oxazolinyl-biphenyle, leur procede de preparation et leur utilisation comme intermediaires de synthese | |
| WO2007104872A1 (fr) | Procede de preparation de dérivés [2-(2,3-dihydro-benzofuran- ou benzofuran-7-yloxy)-ethyl]-(3-cyclopenten-1-yl-benzyl)-amines et intermediaire de synthese | |
| WO2006053985A1 (fr) | Nouveau procede de preparation du 3-[5'-(3,4-bis-hydroxymethyl-benzyloxy)-2'- ethyl-2-propyl-biphenyl-4-yl]-penta-3ol. | |
| EP0184573A1 (fr) | Procédé de préparation d'acides alpha-hydroxy-alcanoiques | |
| HU212733B (en) | Process to prepare (2-benzyloxy-6-nitrophenyl)-acetonitril | |
| EP1097143A1 (fr) | Procede pour la preparation de 5-(1-methylethyl)-6-(phenylmethyl)pyrimidine-2, 4(1h,3h)-dione |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200880014112.5 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08787910 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2683304 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 6353/DELNP/2009 Country of ref document: IN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2008787910 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12594861 Country of ref document: US |